BGJ398 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)
Status:
Completed
Trial end date:
2019-03-25
Target enrollment:
Participant gender:
Summary
The goal of a phase Ib clinical trial is to find the doses of drugs that are safe. Although
BGJ398 has been given to patients safely on its own, it has never been given together with
imatinib mesylate. In this study, we will test the safety of taking BGJ398 with imatinib
mesylate. The investigators will learn this by closely checking for side effects that the
patient may experience. Side effects can be seen in laboratory studies, on physical
examination, or by asking the patient.Once a dose has been determined to be safe, a larger
Phase II study will be done in patients with advanced GIST who have never received any prior
treatments.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Collaborators:
Dana-Farber Cancer Institute M.D. Anderson Cancer Center University of Pittsburgh